Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks - 2Figure out How to Augment Your Rooftop Substitution Speculation
- 3The 20 Most sultry Style of the Time
- 4Trial of pro-Palestine activist begins
- 5Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- America's Confided in Fridge in 2024
- See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- Multi-million-euro win in Spanish lottery in doubt due to oversight
- Israeli forces kill one person in series of attacks on southern Lebanon
- Optimal Beauty Parlor Medicines for Upgraded Wellbeing and Appearance
- 6 Arranging Administrations to Change Your Open air Space
- 10 times the sky amazed us in 2025
- The most effective method to Distinguish the Best Material Organization in Your Space
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
